Immunotherapy drug for treating HPV+ head and neck cancers hailed as "game-changer"

A new generation of “game-changing” drugs that harness the body’s immune system have been found to extend the lives of head and neck cancer sufferers.  The drug, Nivolumab, resulted in the doubling of one-year survival rates in clinical trials on HPV+ head and neck cancer patients.  Findings will be presented to the European Society for Medical Oncology Conference taking place in Copenhagen this week.  Nivolumab works by removing the switch so that immune cells can spot cancer cells and clear them out of the body.  Oracle’s Honorary Trustee, Professor Kevin Harrington, led this exciting trial.

Read the full article here